Evidence map›Paper›PMID 40369175›Full record

ArticleNature cancer2025

Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of esophageal adenocarcinoma.

Melissa Barroux, Jacob Househam, Eszter Lakatos, Tahel Ronel, Ann-Marie Baker, Henrike Salié, Maximilian Mossner, Kane Smith, Chris Kimberley, Salpie Nowinski and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors.

Melissa BarrouxEvolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK. melissa.barroux@mri.tum.de.ORCID http://orcid.org/0000-0002-7682-0932
Jacob HousehamEvolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Eszter LakatosEvolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0002-7221-6850
Tahel RonelEvolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0002-9513-9181
Ann-Marie BakerEvolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0001-8905-9137
Henrike SaliéClinic for Internal Medicine II, University Medical Center Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-2993-3782
Maximilian MossnerEvolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Kane SmithEvolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Chris KimberleyEvolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Salpie NowinskiEvolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Alison BernerEvolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Vinaya GunasriEvolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Martin BorgmannClinic for Internal Medicine II, University Medical Center Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-8195-2796
Sven LiffersBridge Institute of Experimental Tumor Therapy (BIT), Division of Solid Tumor Translational Oncology (DKTK) and Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Marnix JansenDepartment of Pathology, UCL Cancer Institute, University College London, London, UK.ORCID http://orcid.org/0000-0003-0645-564X
Giulio CaravagnaDepartment of Mathematics, Informatics and Geosciences, University of Triest, Triest, Italy.ORCID http://orcid.org/0000-0003-4240-3265
Katja SteigeriBioTUM - Tissue, Institute of Pathology, School of Medicine, TUM, Munich, Germany.ORCID http://orcid.org/0000-0002-7269-5433
Julia Slotta-HuspeninaInstitute of Pathology, Technical University of Munich, Munich, Germany.
Wilko WeichertInstitute of Pathology, Technical University of Munich, Munich, Germany.
Luis ZapataCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Eleftheria GiotaCentre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Sylvie LorenzenDepartment of Internal Medicine III (Haematology/Medical Oncology), Technical University of Munich Hospital Rechts der Isar, Munich, Germany.
Markus AlberstmeierDepartment of General, Visceral and Transplantation Surgery, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany.
Benny ChainDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0002-7417-3970
Helmut FriessDepartment of Surgery, TUM University Hospital, rechts der Isar, School of Medicine and Health, Technical University Munich, Munich, Germany.
Bertram BengschClinic for Internal Medicine II, University Medical Center Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0003-2552-740X
Roland M SchmidMedical Clinic and Polyclinic II, TUM University Hospital, Klinikum rechts der Isar, Munich, Germany.
Jens T SivekeBridge Institute of Experimental Tumor Therapy (BIT), Division of Solid Tumor Translational Oncology (DKTK) and Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID http://orcid.org/0000-0002-8772-4778
Michael QuanteMedical Clinic and Polyclinic II, TUM University Hospital, Klinikum rechts der Isar, Munich, Germany.ORCID http://orcid.org/0000-0002-8497-582X
Trevor A GrahamEvolution and Cancer Laboratory, Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK. trevor.graham@icr.ac.uk.ORCID http://orcid.org/0000-0001-9582-1597

Funding

The Role of the Microbiome in Cancer Suppression and Susceptibility Across SpeciesU54CA217376 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MALEY, CARLO · 2018 to 2022
$8.6M
NCI NIH HHS U54 CA217376
6 · The paper itself

Abstract

Locally advanced esophageal adenocarcinoma remains difficult to treat and the ecological and evolutionary dynamics responsible for resistance and recurrence are incompletely understood. Here, we performed longitudinal multiomic analysis of patients with esophageal adenocarcinoma in the MEMORI trial. Multi-region multi-timepoint whole-exome and paired transcriptome sequencing was performed on 27 patients before, during and after neoadjuvant treatment. We found major transcriptomic changes during treatment with upregulation of immune, stromal and oncogenic pathways. Genetic data revealed that clonal sweeps through treatment were rare. Imaging mass cytometry and T cell receptor sequencing revealed remodeling of the tumor microenvironment during treatment. The presence of genetic immune escape, a less-cytotoxic T cell phenotype and a lack of clonal T cell expansions were linked to poor treatment response. In summary, there were widespread transcriptional and environmental changes through treatment, with limited clonal replacement, suggestive of phenotypic plasticity.

Indexed as

AdenocarcinomaEsophageal NeoplasmsTumor MicroenvironmentAgedFemaleHumansMaleMiddle AgedNeoadjuvant TherapyTranscriptome

Identifiers

PMID40369175
PMCPMC12122370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.